Exploring the Prognostic and chemotherapy Response Potential of CDR1as, circRNA-000284, and circ-ITCH as Circulating Biomarkers in Breast Cancer

Background: Breast cancer is the leading cause of death for women worldwide. Op- timal methods for most cancer control require the use of appropriate biomarkers. Re- cently, circular RNAs (circRNAs), as closed-loop RNA molecules generated through reverse splicing, have emerged as promising biomarkers for cancer development. Methods: In this observation, the expression of 3 unique circRNAs - cdr1as, circR- NA-000284, circ-ITCH - within the peripheral blood of breast cancer patients was studied using Real-Time RT-PCR before and after chemotherapy compared with the control. Results: The data confirmed that the analyzed circRNAs expression was significantly altered in breast cancer patients compared to the controls (p< 0.0001). These altera- tions have been related to advanced stages, lymph node involvement, and metastasis. CircRNA-000284 expression considerably decreased after chemotherapy (p< 0.0001). This may propose its potential as a biomarker for monitoring treatment response. Conclusion: Data suggests that increased expression of circRNA-cdr1as and circR- NA-000284, along with decreased expression of circ-ITCH, are observed in breast can- cer patients. These expression changes are associated with poor prognosis and predic- tion. Additionally, the expression level of circRNA-000284 significantly decreases after chemotherapy, indicating its potential as a candidate marker for studying chemother- apy response. these findings provide valuable insights for the development of novel strategies in the management and treatment of breast cancer. However, further studies are required to validate the clinical utility of these circRNAs as biomarkers and to ex- plore their underlying mechanisms in breast cancer progression

Authors

Institutions

Publication Details

Journal
Basic & Clinical Cancer Research
Published
2025-05-25
DOI
https://doi.org/10.18502/bccr.v15i4.18749
Primary Topic
Circular RNAs in diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Exploring the Prognostic and chemotherapy Response Potential of CDR1as, circRNA-000284, and circ-ITCH as Circulating Biomarkers in Breast Cancer

Mahdieh Salimi, Hossein Mozdarani, Saba Mirzae
1 links
Basic & Clinical Cancer Research
Circular RNAs in diseases
article

Exploring the Prognostic and chemotherapy Response Potential of CDR1as, circRNA-000284, and circ-ITCH as Circulating Biomarkers in Breast Cancer

Mahdieh Salimi, Hossein Mozdarani, Saba Mirzae
article en

Abstract

Background: Breast cancer is the leading cause of death for women worldwide. Op- timal methods for most cancer control require the use of appropriate biomarkers. Re- cently, circular RNAs (circRNAs), as closed-loop RNA molecules generated through reverse splicing, have emerged as promising biomarkers for cancer development. Methods: In this observation, the expression of 3 unique circRNAs - cdr1as, circR- NA-000284, circ-ITCH - within the peripheral blood of breast cancer patients was studied using Real-Time RT-PCR before and after chemotherapy compared with the control. Results: The data confirmed that the analyzed circRNAs expression was significantly altered in breast cancer patients compared to the controls (p< 0.0001). These altera- tions have been related to advanced stages, lymph node involvement, and metastasis. CircRNA-000284 expression considerably decreased after chemotherapy (p< 0.0001). This may propose its potential as a biomarker for monitoring treatment response. Conclusion: Data suggests that increased expression of circRNA-cdr1as and circR- NA-000284, along with decreased expression of circ-ITCH, are observed in breast can- cer patients. These expression changes are associated with poor prognosis and predic- tion. Additionally, the expression level of circRNA-000284 significantly decreases after chemotherapy, indicating its potential as a candidate marker for studying chemother- apy response. these findings provide valuable insights for the development of novel strategies in the management and treatment of breast cancer. However, further studies are required to validate the clinical utility of these circRNAs as biomarkers and to ex- plore their underlying mechanisms in breast cancer progression

Basic & Clinical Cancer Research
Tarbiat Modares University (IR), National Institute of Genetic Engineering and Biotechnology (IR)
Openalex Percentile: Top 90%
Circular RNAs in diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.